Spyre Therapeutics to Present SPY001 Phase 1 Trial Data at DDW 2025 Spyre Therapeutics is set to unveil promising data for SPY001, a groundbreaking treatment for Inflammatory Bowel Disease, during Digestive Disease Week 2025.

Spyre Therapeutics to Present SPY001 Phase 1 Trial Data at DDW 2025 #United_States #San_Diego #Inflammatory_Bowel_Disease #Spyre_Therapeutics #SPY001

Spyre Therapeutics Reports Promising Results and Financial Update for 2024 Spyre Therapeutics unveiled positive trial results and financial growth for 2024, reflecting their commitment to innovative therapies for inflammatory diseases.

Spyre Therapeutics Reports Promising Results and Financial Update for 2024 #USA #Spyre_Therapeutics #Waltham #SPY001 #SPY002